Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Inside Story On How Bayer Swooped On NASDAQ-Bound Vividion

Paying $1.5bn Upfront To Buy Chemoproteomics Specialist

Executive Summary

It has taken just seven weeks from a cold call to completion and the German major has got its hands on a prized asset in Vividion which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.

You may also be interested in...



Bayer’s Vividion Looks To Tavros For Precision Targeting In Cancer

Deal Snapshot: Vividion hopes Tavros’s functional and computational genomics technology will help it discover and validate novel targets in precision oncology therapy.

Bayer Banks On Boston To Achieve Oncology Ambitions

The German major is investing heavily in cancer R&D and has opened the doors of a new facility in the biotech epicenter on the east coast of the US.

BIO 2022 Notebook: Staying Afloat In Rough Waters

News and views from day two of the BIO annual meeting include reflections on the ups and downs of the financing environment, Cerevance CEO Craig Thomson on the challenges of raising VC funds right now, and Bayer business development exec Marianne de Backer explains that it's not a good strategy to buy things just because they are on sale. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel